MedTrace Logo

Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

NCT02391051 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-08-11

No results posted yet for this study

Summary

This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.

Conditions

Interventions

RADIATION

HDR-Brachytherapy

HDR-Brachytherapy 2x 13,5 Gy

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Vratislav Strnad, MD · University Hospital Erlangen, Dept. of Radiooncology

  • Bastian Keck, MD · University Hospital Erlangen, Dept. of Urology

  • Alexander Cavallaro, MD · University Hospital Erlangen, Dept. of Radiology

  • Arndt Hartmann, MD · University Hospital Erlangen, Dept. of Pathology

  • Michael Lotter, Dipl.-Phys. · University Hospital Erlangen, Dept. of Radiooncology

  • Annedore Strnad, MD, MHBA · University Hospital Erlangen, Dept. of Radiooncology

  • Peter Goebell, MD · University Hospital Erlangen, Dept. of Urology

  • Wolfgang Uter, MD · University Erlangen; Dept. of Biometrics and Epidemiology

  • Michael Uder, MD · University Hospital Erlangen, Dept. of Radiology

  • Bernd Wullich, MD · University Hospital Erlangen, Dept. of Urology

  • Rainer Fietkau, MD · University Hospital Erlangen, Dept. of Radiooncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2019-12-31
Completion
2029-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02391051 on ClinicalTrials.gov